ÂÜÀòÂÒÂ×

Dr. Ross Levine is a Member of the Human Oncology and Pathogenesis Program (HOPP) and an Attending Physician on the Leukemia Service, Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). He is the Chief of the Molecular Cancer Medicine Service, the Laurence Joseph Dineen Chair in Leukemia Research, a Professor of Medicine at Weill Cornell Medical College, and the Director of the MSK Center for Hematologic Malignancies. Dr. Levine earned his A.B. from Harvard College and M.D. from Johns Hopkins University School of Medicine. Dr. Levine served as a Resident in Internal Medicine at Massachusetts General Hospital and as a Hematology-Oncology Fellow at Dana-Farber Cancer Institute. His laboratory has identified myeloproliferative neoplasm (MPN) predisposition alleles and characterized somatic genetic and epigenetic alterations in MPN and acute myeloid leukemia (AML) patients, which has led to new mechanism-based therapies. In 2011, he was elected to the American Society of Clinical Investigation and in 2018 to the Association of American Physicians. He serves on the Supervisory Board of Qiagen N.V. (NYSE: QGEN) and on the Scientific Advisory Boards of C4 Therapeutics (NASDAQ: CCCC), Zentalis Pharmaceuticals (NASDAQ: ZNTL), Prelude Therapeutics (NASDAQ: PRLD), Scorpion Therapeutics and Mission Bio. He was also on the Scientific Advisory Board of Loxo Oncology (acquired by Eli Lilly).